ERBB2 and neoplasm: (2) For patients with high levels of CA199 and CA125, preoperative neoadjuvant therapy (such as chemotherapy combined with anti angiogenic drugs) can be considered to reduce tumor burden and postoperative recurrence; (3) Although the importance of Erb-B2 is relatively low, its inclusion in the model as a target for approved targeted drugs (such as trastuzumab) provides a basis for precise stratification and targeted therapy.